Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Case report

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report

Authors: Yuchen Jin, Min Liu, Lingxiao Cheng, Libo Chen

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Pregnancy is an unquantifiable risk to accelerate tumor growth of papillary thyroid carcinoma (PTC), and whether pregnancy induces an unfavorable prognosis of radioiodine refractory papillary thyroid carcinoma (RR-PTC) remains unknown.

Case presentation

We investigated the impact of pregnancy on the prognosis of pulmonary metastases in an RR-PTC woman via a long-term clinical follow-up and consecutive computed tomography examinations and serum tests. After a successful pregnancy, the metastatic lesions shrank with serum thyroglobulin slightly fluctuated under sustained thyroid stimulating hormone (TSH) suppression, demonstrating a favorable outcome.

Conclusions

This case study indicates that metastatic RR-PTC may not be aggravated by pregnancy under TSH suppression, and pregnancy should not be contraindicated in RR-PTC patients with stable disease.
Literature
1.
Capdevila J, Galofre JC, Grande E, Zafon Llopis C, Ramon YCAT, Navarro Gonzalez E, Jimenez-Fonseca P, Santamaria Sandi J, Gomez Saez JM, Riesco Eizaguirre G. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish rare cancer working group (GETHI). Clin Transl Oncol. 2017;19(3):279–87.CrossRefPubMed
2.
3.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2016;26(1):1–133.CrossRef
4.
Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997;82(9):2862–6.CrossRefPubMed
5.
Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B, Smith LH. Thyroid cancer in pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2005;91(1):15–20.CrossRef
6.
Sturniolo G, Zafon C, Moleti M, Castellvi J, Vermiglio F, Mesa J. Immunohistochemical expression of estrogen receptor-alpha and progesterone receptor in patients with papillary thyroid cancer. European thyroid journal. 2016;5(4):224–30.CrossRefPubMedPubMedCentral
7.
Rowe CW, Murray K, woods a, Gupta S, smith R, Wynne K. management of metastatic thyroid cancer in pregnancy: risk and uncertainty. Endocrinol Diabetes Metab Case Rep. 2016;2016
8.
Murray JR, Williams GR, Harrington KJ, Newbold K, Nutting CM. Rising thyroglobulin tumour marker during pregnancy in a thyroid cancer patient: no cause for alarm? Clin Endocrinol. 2012;77(1):155–7.CrossRef
Metadata
Title
Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
Authors
Yuchen Jin
Min Liu
Lingxiao Cheng
Libo Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3717-3

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer

Research article

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

Research article

RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma

Research article

Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line

Research article

Dietary supplement use among cancer survivors and the general population: a nation-wide cross-sectional study

Research article

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits